SystImmune and Bristol Myers Squibb Secure Breakthrough Therapy Designation for Cancer Treatment SystImmune and Bristol Myers Squibb have received Breakthrough Therapy Designation for izalontamab brengitecan to treat advanced lung cancer, offering new hope to patients.

SystImmune and Bristol Myers Squibb Secure Breakthrough Therapy Designation for Cancer Treatment #United_States #SystImmune #Redmond #Izalontamab_Brengitecan #EGFR_Mutated_Lung_Cancer